Haematologica · 2009 · 113 citations · 16 references
MedicineHematologyImmunologyStem Cell BiologyStem Cell TransplantationTransplant ImmunologyAllogeneic Stem Cell TransplantationDonor-recipient CompatibilityEngraftment MonitoringMinimal Residual DiseaseMyelodysplastic SyndromesRelapsed DiseaseAllogeneic Stem Cell TherapyDonor-recipient ChimerismMinimal Residual Disease MarkersPositive Predictive ValuePost-transplant ChimerismPost-transplant Residual Disease MonitoringRelapse Risk After TransplantationRelapsed Acute Myeloid Leukemia
Analysis of donor chimerism is an important diagnostic tool to assess the risk of relapse after allogeneic stem cell transplantation, especially in patients lacking a specific marker suitable for monitoring of minimal residual disease. We prospectively investigated the predictive value of donor chimerism analyses in sorted CD34(+) peripheral blood cells in 90 patients with acute leukemia and myelodysplastic syndrome. The cumulative incidence of relapse after four years was significantly increased in cases with decreasing or incomplete CD34(+) donor chimerism (57% vs. 18%, p=0.0001). Multivariate analysis confirmed decreasing CD34(+) donor chimerism as an independent predictor of relapse and inferior survival. The interval between a decrease of CD34(+) chimerism of less than 80% and hematologic relapse was 61 days (range 0-567). Monitoring of CD34(+) donor chimerism in the peripheral blood allows prediction of imminent relapse after allogeneic stem cell transplantation even when a disease-specific marker is lacking.
16
Christoph Schmid, Michael Schleuning, Georg Ledderose et al. · Journal of Clinical Oncology · 2005 · 419 citations
Medicine, Oncology, Cell Therapy +15